As a deadly Ebola outbreak in the Democratic Republic of Congo continues to outpace efforts to contain it, help may be on the way in the form of a new vaccine being tested in Canada. Health Canada has authorized a phase 1 clinical trial for a potential mRNA vaccine aimed at the Bundibugyo strain of the virus, the strain behind the current outbreak. It marks an early but significant step toward a tool that does not yet exist for this form of the disease.
The Canadian trial has enrolled 80 healthy volunteers, and the first dose was administered in Truro, Nova Scotia, on Sunday. The vaccine is being developed by the drugmaker Moderna, which says the technology builds on the same mRNA methods the company used to develop its COVID-19 vaccine. That platform allowed for rapid development during the pandemic and is now being turned toward Ebola.
As an early-stage study, the phase 1 trial is designed to answer basic safety and dosing questions. Researchers will look to determine any side effects, establish the appropriate dosage, and test whether the immune system mounts a response to the vaccine. Those results will help decide whether the candidate should be advanced through further stages of testing.
The stakes are high because there is currently no approved treatment or vaccine for this rare strain of Ebola. Scientists are hoping to change that, and officials describe promising progress across several fronts, with clinical trials underway for treatment, for prophylaxis, and for vaccines. The Canadian study is part of that broader push to build defenses against a virus that has so far had none tailored to it.
The urgency is driven by the scale of the outbreak in the Democratic Republic of Congo. Officials say it is now the second largest Ebola outbreak ever recorded. According to the World Health Organization, the outbreak has killed about 1,700 people and infected nearly 3,800 since it began in mid-May, and it has continued to spread faster than responders can keep up.
On the ground, the response is straining under that pressure. Workers have been pushing to finish a new facility for Ebola patients to keep pace with the unprecedented spread of the virus. The country's biggest treatment center is already at its capacity of 100 beds, underscoring how quickly the caseload has outgrown the resources available to treat it.
Compounding the medical emergency is an ongoing conflict in the region, which has forced mass displacements and fueled widespread mistrust of health authorities. Those conditions make it harder to track cases, isolate patients and deliver care, and they are part of why the outbreak has proven so difficult to bring under control even as vaccine research like the Canadian trial moves forward.